Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology
Retrieved on:
Friday, September 30, 2022
Penicillamine, Adult, Observation, Yale University, Brain, FDA, Disease, Center, Blood, Excellence, LinkedIn, Triethylenetetramine, Center of excellence, Wilson, Maintenance, Patient, Copper, Physician, III, Ceruloplasmin, Serum, Genetic disorder, SAE, Liver, NCC, Method, Degenerative disease, Research, Unified, Wilson's disease, Șaeș, Pharmaceutical industry, Plumbing, Medical imaging
It was the first treatment for Wilson's disease to be approved by the FDA in over five decades.
Key Points:
- It was the first treatment for Wilson's disease to be approved by the FDA in over five decades.
- During the trial, an innovative assay was developed to measure non-caeruloplasmin bound copper (NCC), the free and potentially toxic pool of copper in the blood.
- The results of the CHELATE trial mark an important milestone for the Wilsons disease community, providing further evidence on the efficacy of trientine tetrahydrochloride for prescribing physicians and evidence-based options for patients.
- Orphalan commercializes Cuprior, its trientine tetrahydrochloride product for the treatment of Wilsons disease in Europe, and will be launching Cuvrior, recently approved by the FDA, in the US.